Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and solid organ transplantation.

I F Gazi1, E N Liberopoulos, V G Athyros

  • 1Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College of Medicine, University of London, Pond Street, London NW3 2QG, UK.

Current Pharmaceutical Design
|December 16, 2006
PubMed
Summary

Statins are effective and safe for managing dyslipidemia in solid organ transplant recipients, improving survival and reducing cardiovascular events and rejection. Close monitoring for side effects is recommended due to interactions with immunosuppressants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.

Current vascular pharmacology·2023
Same author

Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency.

Current vascular pharmacology·2023
Same author

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Digestive diseases and sciences·2021
Same author

Multifocal arterial disease: clinical implications and management.

Current opinion in cardiology·2020
Same author

Preface.

Current vascular pharmacology·2018
Same author

Daylight saving time and myocardial infarction: should we be worried? A review of the evidence.

European review for medical and pharmacological sciences·2018

Area of Science:

  • Medical Science
  • Pharmacology
  • Transplant Medicine

Background:

  • Dyslipidemia is prevalent in solid organ transplant recipients.
  • It is linked to chronic rejection, atherosclerosis, and increased cardiovascular disease (CVD) risk.
  • CVD is a leading cause of death in transplant patients.

Purpose of the Study:

  • To review the benefits of statins in solid organ transplant recipients (adults and children).
  • To examine combination therapy with ezetimibe and statins.
  • To assess the safety and efficacy of statins in this unique patient population.

Main Methods:

  • Review of clinical trials and studies on statin use in transplant recipients.
  • Analysis of data on dyslipidemia management, CVD events, rejection rates, and survival.

Related Experiment Videos

  • Consideration of drug interactions, particularly with immunosuppressive therapy.

    • Main Results:

    • Statins are efficient and safe for treating dyslipidemia in transplant patients.
    • Statins demonstrated beneficial effects on long-term survival, CVD events, and rejection rates in most trials.
    • Combination therapy with ezetimibe and statins was also considered.

    Conclusions:

    • Statins are recommended for dyslipidemic transplant patients at appropriate dosages.
    • Close monitoring for adverse effects is crucial due to immunosuppressive therapy.
    • Statins offer significant benefits for managing dyslipidemia and improving outcomes in transplant recipients.